Compare GCT & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GCT | VERA |
|---|---|---|
| Founded | 2019 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2022 | 2021 |
| Metric | GCT | VERA |
|---|---|---|
| Price | $37.71 | $46.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | $24.00 | ★ $66.89 |
| AVG Volume (30 Days) | 631.9K | ★ 1.9M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.32 | N/A |
| EPS | ★ 3.31 | N/A |
| Revenue | ★ $1,222,932,000.00 | N/A |
| Revenue This Year | $9.56 | N/A |
| Revenue Next Year | $7.08 | N/A |
| P/E Ratio | $11.60 | ★ N/A |
| Revenue Growth | ★ 10.17 | N/A |
| 52 Week Low | $11.17 | $18.53 |
| 52 Week High | $40.75 | $48.49 |
| Indicator | GCT | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | 80.16 |
| Support Level | $38.27 | $40.38 |
| Resistance Level | $40.75 | $47.10 |
| Average True Range (ATR) | 1.70 | 3.09 |
| MACD | -0.02 | 1.29 |
| Stochastic Oscillator | 71.29 | 96.03 |
GigaCloud Technology Inc provides end-to-end and B2B e-commerce solutions for large parcel merchandise. Its B2B e-commerce platform, which is referred to as the GigaCloud Marketplace, integrates everything from discovery, payments, and logistics tools into one easy-to-use platform. It offers online and offline integrated cross-border transaction and delivery services for furniture and large merchandise. Its marketplace seamlessly connects manufacturers in Asia, with resellers in the U.S., Asia, and Europe, to execute cross-border transactions with confidence, speed, and efficiency. It offers a truly comprehensive solution that transports products from the manufacturer's warehouse to end customers, all at one fixed price.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.